Insider Transactions Reported by 12 Insiders of Gain Therapeutics, Inc.

Symbol
GANX on Nasdaq
Location
Bethesda, MD

There are no Buy or Sell transactions made by insiders since 18 Mar 2025

Gain Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Eric I. Richman Director $1,174,903 24 Jun 2025
Khalid Islam Director $929,667 24 Jun 2025
Charles Evan Ballantyne Chief Financial Officer $125,000 10 Apr 2023
Matthias Alder Chief Executive Officer, Director $110,433 26 Mar 2024
Salvatore Calabrese Chief Financial Officer $62,500 23 Mar 2023
Gene Mack CEO, President, Director $14,544 20 Mar 2025
Gwen A. Melincoff Director 24 Jun 2025
Jeffrey Scott Riley Director 24 Jun 2025
Dov A. Goldstein MD Director 24 Jun 2025
Claude Nicaise Director 24 Jun 2025
Hans Peter Hasler Director 24 Jun 2025
Gianluca Fuggetta Principal Accounting and Financial Officer 20 Mar 2025

Recent Insider Transactions by Companies or Individuals for Gain Therapeutics, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Khalid Islam GANX Stock Option (right to buy) Award 15,000 15,000 24 Jun 2025 Direct
Claude Nicaise GANX Stock Option (right to buy) Award 15,000 15,000 24 Jun 2025 Direct
Jeffrey Scott Riley GANX Stock Option (right to buy) Award 15,000 15,000 24 Jun 2025 Direct
Eric I. Richman GANX Stock Option (right to buy) Award 15,000 15,000 24 Jun 2025 Direct
Hans Peter Hasler GANX Stock Option (right to buy) Award 15,000 15,000 24 Jun 2025 Direct
Dov A. Goldstein MD GANX Stock Option (right to buy) Award 15,000 15,000 24 Jun 2025 Direct
Gwen A. Melincoff GANX Stock Option (right to buy) Award 15,000 15,000 24 Jun 2025 Direct
Gianluca Fuggetta GANX Employee Stock Option (right to buy) Award 50,000 50,000 20 Mar 2025 Direct
Gene Mack GANX Employee Stock Option (right to buy) Award 200,000 200,000 20 Mar 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.